Bliss GVS Pharma Ltd. News, Corporate filings and Earnings/Conference Calls

Keep track of all breaking news and updates on Bliss GVS Pharma Ltd. from all sources in a single place.

Load latest

Bliss GVS Pharma Ltd.

15 May 2023

150.53

-1.92%

Company Update

BLISS GVS PHARMA LTD. - 506197 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

Pursuant to the provision of Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the extract copies of the newspaper advertisement of the Audited Financial Results of the Company for the quarter and year ended March 31, 2023, published in 'The Economic Times & The Free Press Journal' an English Daily and 'Maharashtra Times & Navshakti' a Regional Daily, on May 13, 2023.

pdf

Bliss GVS Pharma Ltd.

15 May 2023

150.53

-1.92%

Corp. Note

BLISS GVS PHARMA LTD. - 506197 - Format of the Annual Disclosure to be made by …

BSE India

Format of the Annual Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1 Name of Company BLISS GVS PHARMA LTD. 2 CIN NO. L24230MH1984PLC034771 3 Report filed for FY 2022-2023 Details of the Current block (all figures in Rs crore): 4 2 - year block period (Specify financial years)* FY 2022-2023; FY 2023-2024 5 Incremental borrowing done in FY (T)(a) 0.00 6 Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a) 0.00 7 Actual borrowing done through debt securities in FY (T)(c) 0.00 8 Shortfall in the borrowing through debt securities, if any, for FY (T - 1) carried forward to FY (T) (d) 0 8Quantum of (d), which has been met from (c)(e)* 0 9 Shortfall, if any, in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)}(f) = (b) - [(c) - (e)]{ If the calculated value is zero or negative, write 'nil'}* 0 Details of penalty to be paid, if any, in respect to previous block (all figures in Rs crore): 2 - year Block period (Specify financial years)FY 2022-2023; FY 2021-2022 Amount of fine to be paid for the block, if applicable Fine = 0.2% of {(d) - (e)}#0.00 Name of the Company Secretary :-Aditi BhattDesignation :-Company Secretary Name of the Chief Financial Officer :- Deepak Sawant Designation : -Chief Financial Officer Date: 15/05/2023

pdf

Bliss GVS Pharma Ltd.

12 May 2023

150.53

-1.92%

Company Update

BLISS GVS PHARMA LTD. - 506197 - Grant Of Options Under Bliss GVS Pharma Limited - …

BSE India

Pursuant to Regulation 30 of Securities and Exchange Board of India (SEBI) (Listing Obligations and Disclosure Requirements) Regulations, 2015 (''Listing Regulations'') read with Para B of Part A of Schedule III of Listing Regulations and SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 09, 2015, we would like to inform you that the Members of the Nomination and Remuneration Committee of Bliss GVS Pharma Limited ('the Company') in its meeting held yesterday i.e. May 11, 2023, has granted 11,55,000 Employee Stock Options under Bliss GVS Pharma Limited- Employee Stock Options Plan 2019 to the eligible employees of the Company.

pdf

Bliss GVS Pharma Ltd.

12 May 2023

150.53

-1.92%

Corp. Action

BLISS GVS PHARMA LTD. - 506197 - Intimation Of Book Closure In Accordance With Regulation 42 …

BSE India

Pursuant to Section 91 of the Companies Act, 2013 ('Act'') and applicable Regulations of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") read with our intimation submitted to you w.r.t. Final Dividend on May 11, 2023, the Register of Members and Share Transfer Books of the Company will remain closed from Thursday, July 13, 2023 to Wednesday, July 19, 2023 (both the days inclusive) for taking on record of the members of the Company for the purpose of holding 38th Annual General Meeting of the Company which will be held on Wednesday, July 19, 2023 for the financial year ended March 31, 2023 and payment of Final Dividend for the financial year ended March 31, 2023.

pdf

Bliss GVS Pharma Ltd.

12 May 2023

150.53

-1.92%

Annual Report

BSE India

Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyBLISS GVS PHARMA LTD. 2CIN NO.L24230MH1984PLC034771 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 52.05 4Highest Credit Rating during the previous FY IVRBBBSTABLE 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)INFOMERICS VALUATION AND RATING PVT. LTD. 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Aditi Bhatt Designation: Company Secretary EmailId: cs@blissgvs.com Name of the Chief Financial Officer: Deepak Sawant Designation: Chief Financial Officer EmailId: deepak.sawant@blissgvs.com Date: 28/04/2023 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.

pdf

Is Bliss GVS Pharma Ltd. worth buying?

169 Votes:

Buy 81.07%

Sell 8.88%

Hold 10.06%